International Stem Cell CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
International Stem Cell Corporation reported a net income of $57,000 for Q3 2025, a significant improvement from the prior year's loss, but continues to raise substantial doubt about its ability to continue as a going concern.
OQB
International Stem Cell Corporation reported a wider net loss of $127,000 for the first six months of 2025, alongside a going concern warning, despite increased product sales and significant R&D investment.
OQB
International Stem Cell Corporation's Q1 2025 results show stable revenue with ongoing efforts to secure additional funding for research and development.
OQB
International Stem Cell Corporation's Q3 2024 results show increased product sales but continued net losses and concerns about the company's ability to continue as a going concern.
OQB
10-Q: International Stem Cell Corporation Reports Mixed Q2 Results with Revenue Growth Offset by Net Loss
International Stem Cell Corporation's Q2 2024 results show a revenue increase driven by biomedical sales, but the company still reports a net loss and faces going concern challenges.
OQB
International Stem Cell Corporation's first quarter 2024 results show a slight increase in product sales but a larger net loss compared to the same period last year.